ARCHIVES

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

This article is from The Cancer Letter archive.

Vol. 29 No. 46 | December 12, 2003

Download PDF Visit The Full Archive

Related Articles

Test May Identify Predictors For Recurrence Post-Surgery

January 28, 2011

Cancer Panel: Lack Of Genetic Basis For Race Presents Dilemma For Studies; Data Collection Must Include Socioeconomic Measures, Report To Clinton Says

March 20, 1998

AACR Meeting: Celebrex Studies Show Benign Polyp Reduction, Point To Challenges In Biomarker Validation.

April 14, 2006

ACCC Established FCCC Special Interest Group

April 11, 1986

FDA Approves Merck’s Gardasil Vaccine To Prevent Cervical Cancer.

June 9, 2006

Half-Percent NIH, NCI Budget Raise Is Not Enough, Advocates Say

December 19, 2014